Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)

NCT07591753 · clinicaltrials.gov ↗

COMPLETED

Status

591

Enrollment

NETWORK

Sponsor class

Conditions

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)

Interventions

BIOLOGICAL: Mepolizumab 300 mg

Sponsor

European EGPA Study Group

Collaborators

[object Object]